Generic levothyroxine: What is all the fuss about?

Endocrine Practice

Volumn 11, Issue 3, 2005, Pages 205-207

  Garber, Jeffrey R ^a   Hennessey, James V ^b  

^a Harvard Vangard ^*  (United States)

^b Hallett Center for Diabetes and Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; THYROTROPIN; THYROXINE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL LABORATORY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; HORMONE DETERMINATION; HYPERTHYROIDISM; HYPOTHYROIDISM; MEDICAL PRACTICE; METHODOLOGY; NOTE; PRESCRIPTION; SENSITIVITY AND SPECIFICITY; THYROID FUNCTION; UNITED STATES; ARTICLE; CHEMISTRY; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLISM; PHARMACOKINETICS; THYROID DISEASE;

CHEMISTRY, PHARMACEUTICAL; HUMANS; LEGISLATION, DRUG; THERAPEUTIC EQUIVALENCY; THYROID DISEASES; THYROXINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 27744554848     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.3.205     Document Type: Note

References (15)

1. http://www.aace.com/clin/guidelines/AACE-TES-ATA-ThyroxineProducts.pdf.
2. http://www.endo-society.org/news/thyroxine-position-statement.cfm.
3. http://www.thyroid.org/professionals/advocacy/04_12_08_thyroxine.html.
4. Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 2004;14:191-200.
5. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2002;12:421-425.
6. Sawin CT. Subclinical hyperthyroidism and atrial fibrillation. Thyroid. 2002;12:501-503.
7. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130: 350-356.
8. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549-555.
9. http://www.thyroid.org/professionals/advocacy/04_03_19_fda.html.
10. Synthroid Study AA03790. Comparing Sandoz Levothyroxine to Synthroid: Sandoz Introduces Levothyroxine Sodium Tablets, USP; A Bioequivalent Alternative Product to Synthroid and Levoxyl. Sandoz Publications. July 2004; 17000-26.
11. Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf). 1988;28:325-333.
12. http://www.fda.gov/cder/orange/supplement/cspreface.htm.
13. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
14. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534.
15. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. An evaluation of the adequacy of outpatient monitoring of thyroid replacement therapy. J Eval Clin Pract. 2004;10:525-530.